The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases

FEBS Journal

Volumn 280, Issue 12, 2013, Pages 2830-2841

  Krishnan, Navasona ^a   Bencze, Gyula ^a   Cohen, Philip ^b   Tonks, Nicholas K ^a  

^a Simons Center for Quantitative Biology   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

anti inflammatory; covalent inhibitor; kinase; Michael acceptor; phosphatase

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; CATALASE; CYSTEINE; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 10; DUAL SPECIFICITY PHOSPHATASE 14; DUAL SPECIFICITY PHOSPHATASE 16; DUAL SPECIFICITY PHOSPHATASE 4; HYDROGEN PEROXIDE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 12; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE ALPHA; UNCLASSIFIED DRUG; VANADATE SODIUM;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CATALYTIC DOMAIN; CELL LINE; ENZYME INHIBITORS; HUMANS; KINETICS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MODELS, MOLECULAR; NITRILES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; SULFONES; SURFACE PROPERTIES; TYROSINE; VANADATES;

EID: 84878767986     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12283     Document Type: Article

References (38)

1. Tonks NK, (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7, 833-846.
2. Tonks NK, (2003) PTP1B: from the sidelines to the front lines!. FEBS Lett 546, 140-148.
3. Ostergaard HL, Shackelford DA, Hurley TR, Johnson P, Hyman R, Sefton BM, &, Trowbridge IS, (1989) Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines. Proc Natl Acad Sci USA 86, 8959-8963.
4. Koretzky GA, Picus J, Thomas ML, &, Weiss A, (1990) Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway. Nature 346, 66-68.
5. Tonks NK, &, Muthuswamy SK, (2007) A brake becomes an accelerator: PTP1B-a new therapeutic target for breast cancer. Cancer Cell 11, 214-216.
6. Neel BG, Gu H, &, Pao L, (2003) The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28, 284-293.
7. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, et al,. (2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64, 8816-8820.
8. Wang S, Yu WM, Zhang W, McCrae KR, Neel BG, &, Qu CK, (2009) Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis. J Biol Chem 284, 913-920.
9. Lin G, Aranda V, Muthuswamy SK, &, Tonks NK, (2011) Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev 25, 1412-1425.
10. Barford D, Flint AJ, &, Tonks NK, (1994) Crystal structure of human protein tyrosine phosphatase 1B. Science 263, 1397-1404.
11. Lou YW, Chen YY, Hsu SF, Chen RK, Lee CL, Khoo KH, Tonks NK, &, Meng TC, (2008) Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells. FEBS J 275, 69-88.
12. Meng TC, Buckley DA, Galic S, Tiganis T, &, Tonks NK, (2004) Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. J Biol Chem 279, 37716-37725.
13. Tonks NK, (2005) Redox redux: revisiting PTPs and the control of cell signaling. Cell 121, 667-670.
14. Liu S, Zhou B, Yang H, He Y, Jiang ZX, Kumar S, Wu L, &, Zhang ZY, (2008) Aryl vinyl sulfonates and sulfones as active site-directed and mechanism-based probes for protein tyrosine phosphatases. J Am Chem Soc 130, 8251-8260.
15. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, &, Gerritsen ME, (1997) Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272, 21096-21103.
16. Zanotto-Filho A, Delgado-Canedo A, Schroder R, Becker M, Klamt F, &, Moreira JC, (2010) The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett 288, 192-203.
17. Krishnan N, Fu C, Pappin DJ, &, Tonks NK, (2011) H2S-induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci Signal 4, ra86.
18. Boivin B, &, Tonks NK, (2010) Analysis of the redox regulation of protein tyrosine phosphatase superfamily members utilizing a cysteinyl-labeling assay. Methods Enzymol 474, 35-50.
19. Boivin B, Yang M, &, Tonks NK, (2010) Targeting the reversibly oxidized protein tyrosine phosphatase superfamily. Sci Signal 3, pl2.
20. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, &, Barford D, (2003) Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423, 769-773.
21. Tonks NK, (2013) Protein tyrosine phosphatases: from housekeeping enzymes to master-regulators of signal transduction. FEBS J 280, 346-378.
22. Lee J, Rhee MH, Kim E, &, Cho JY, (2012) BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm 2012, 416036.
23. Miyamoto R, Ito T, Nomura S, Amakawa R, Amuro H, Katashiba Y, Ogata M, Murakami N, Shimamoto K, Yamazaki C, et al,. (2010) Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. Arthritis Res Ther 12, R87.
24. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, &, Jacks T, (2011) Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1, 236-247.
25. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, Shpiro N, &, Cohen P, (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signaling network by targeting the ubiquitin system. Biochem J 451, 427-437.
26. White DE, &, Burchill SA, (2008) BAY 11-7082 induces cell death through NF-kappaB-independent mechanisms in the Ewing's sarcoma family of tumours. Cancer Lett 268, 212-224.
27. Min KJ, Lee JT, Joe EH, &, Kwon TK, (2011) An IkappaBalpha phosphorylation inhibitor induces heme oxygenase-1 (HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-kappaB-independent mechanism. Cell Signal 23, 1505-1513.
28. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP, et al,. (2010) Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem 285, 9792-9802.
29. Burke TR Jr, Ye B, Yan X, Wang S, Jia Z, Chen L, Zhang ZY, &, Barford D, (1996) Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry 35, 15989-15996.
30. Andersen JN, &, Tonks NK, (2004) Protein tyrosine phosphatase-based therapeutics: lessons from PTP1B. Top Curr Genet 5, 201-230.
31. Loll PJ, Picot D, &, Garavito RM, (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2, 637-643.
32. Vane JR, (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231, 232-235.
33. Singh J, Petter RC, Baillie TA, &, Whitty A, (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10, 307-317.
34. Singh J, Petter RC, &, Kluge AF, (2010) Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 14, 475-480.
35. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al,. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107, 13075-13080.
36. Yang Y, Shaffer AL III, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, et al,. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723-737.
37. Labbe DP, Hardy S, &, Tremblay ML, (2012) Protein tyrosine phosphatases in cancer: friends and foes!. Prog Mol Biol Transl Sci 106, 253-306.
38. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, &, Zhang ZY, (1997) Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci USA 94, 13420-13425.